Therapeutic regulation of complement in patients with renal disease - Where is the promise?

Clinical Nephrology

Volumn 77, Issue 5, 2012, Pages 413-423

  Thurman, Johua M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Complement inhibitors; Eculizumab; Glomerulonephritis; Renal desease

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C9; COMPLEMENT INHIBITOR; ECULIZUMAB;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DENSE DEPOSIT DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; IMMUNOREGULATION; INFECTION RISK; INNATE IMMUNITY; KIDNEY BIOPSY; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN BLOOD LEVEL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY; KIDNEY DISEASES; TREATMENT OUTCOME;

EID: 84861510183     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107220     Document Type: Article

References (89)

1. Verroust PJ, Wilson CB, Cooper NR, Edgington TS, Dixon FJ. Glomerular complement components in human glomerulonephritis. J Clin Invest. 1974; 53: 77-84. doi:10.1172/JCI107562 PubMed
2. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 2003; 198: 913-923. doi:10.1084/jem.20030374 PubMed
3. Couser WG. Complement inhibitors and glomerulonephritis: are we there yet? J Am Soc Nephrol. 2003; 14: 815-818. doi:10.1097/01. ASN.0000057502.76239.7D PubMed
4. Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, Mojcik CF, Rother RP. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005; 106: 2559-2565. doi:10.1182/blood-2005-02-05 64 PubMed
5. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004; 350: 552-559. doi:10.1056/ NEJMoa031688 PubMed
6. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011; 26: 613-619. doi:10.1007/s00467-010-170 8-6 PubMed
7. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360: 544-546. doi:10.1056/NEJMc 08 0 9959 PubMed
8. Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-Hassociated atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011; 26: 621-624. doi:10.1007/ s00467-010-1719-3 PubMed
9. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009; 9: 231-235. doi:10.1111 /j.160 0-6 14 3.2008.02451.x PubMed
10. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009; 4: 1312-1316. doi:10.2215/ CJN.01090209 PubMed
11. Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360: 542-544. doi:10.1056/ NEJMc0808527 PubMed
12. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med. 2010; 362: 1746-1748. doi:10.1056/NEJMc1001060 PubMed
13. Walport MJ. Complement. First of two parts. N Engl J Med. 2001; 344: 1058-1066. PubMed
14. Cole DS, Morgan BP. Beyond lysis: how complement influences cell fate. Clin Sci (Lond). 2003; 104: 455-466. doi:10.1042/CS20020362 PubMed
15. Takahashi K, Ip WE, Michelow IC, Ezekowitz RA. The mannose-binding lectin: a prototypic pattern recognition molecule. Curr Opin Immunol. 2006; 18: 16-23. doi:10.1016/j.coi.2005.11.014 PubMed
16. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000; 164: 786-794. PubMed
17. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006; 176: 1305-1310. PubMed
18. Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol. 2008; 151: 210-230. doi:10.1111/j.1365-2 249.2007.03574.x PubMed
19. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007; 7: 518-526. doi:10.1111/j.1600-61 43.2006.01688.x PubMed
20. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006; 17: 1724-1734. doi:10.1681/ASN.2005 09 0923 PubMed
21. Lhotta K, Würzner R, König P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant. 1999; 14: 881-886. doi:10.1093/ndt/14.4.881 PubMed
22. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannanbinding lectin pathway. J Immunol. 2001; 167: 2861-2868. PubMed
23. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol. 2001; 159: 1045-1054. doi:10.1016/S0002-9440(10)61779-8 PubMed
24. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007; 170: 52-64. doi:10.2353/ajpath.2007.060573 PubMed
25. Lenderink AM, Liegel K, Ljubanović D, Coleman KE, Gilkeson GS, Holers VM, Thurman JM. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol. 2007; 293: F555-F564. doi:10.1152/ajprenal. 00403.2006 PubMed
26. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol. 1999; 10: 2323-2331. PubMed
27. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003; 170: 1517-1523. PubMed
28. Brandt J, Pippin J, Schulze M, Hänsch GM, Alpers CE, Johnson RJ, Gordon K, Couser WG. Role of the complement membrane attack complex (C5b- 9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int. 1996; 49: 335-343. doi:10.1038/ki.1996.50 PubMed
29. Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest. 1980; 66: 1339-1350. doi:10.1172/JCI109987 PubMed
30. Tang Z, Lu B, Hatch E, Sacks SH, Sheerin NS. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol. 2009; 20: 593-603. doi:10.1681/ASN.2008040434 PubMed
31. Bao L, Osawe I, Haas M, Quigg RJ. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol. 2005; 175: 1947-1955. PubMed
32. Li Q, Peng Q, Xing G, Li K, Wang N, Farrar CA, Meader L, Sacks SH, Zhou W. Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol. 2010; 21: 1344-1353. doi:10.1681/ ASN.2009090977 PubMed
33. Rangan GK, Pippin JW, Couser WG. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int. 2004; 66: 1838-1848. doi:10.111 1/j .1523-1755.2004.00957.x PubMed
34. Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementemia. Kidney Int. 1991; 39: 811-821. doi:10.1038/ki.1991.102 PubMed
35. Porcel JM, Ordi J, Castro-Salomo A, Vilardell M, Rodrigo MJ, Gene T, Warburton F, Kraus M, Vergani D. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol. 1995; 74: 283-288. doi:10.1006/clin.1995.1040 PubMed
36. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum. 1992; 35: 1028-1037. doi:10.1002/art.1780350907 PubMed
37. Abou-Ragheb HH, Williams AJ, Brown CB, Milford-Ward A. Plasma levels of the anaphylatoxins C3a and C4a in patients with IgA nephropathy/ Henoch-Schönlein nephritis. Nephron. 1992; 62: 22-26. doi:10.1159/000186989 PubMed
38. Wyatt RJ, Julian BA. Activation of complement in IgA nephropathy. Am J Kidney Dis. 1988; 12: 437-442. PubMed
39. Brenchley PE, Coupes B, Short CD, O'Donoghue DJ, Ballardie FW, Mallick NP. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int. 1992; 41: 933-937. doi:10.1038/ki.1992.143 PubMed
40. Prescott HC, Wu HM, Cataland SR, Baiocchi RA. Eculizumab therapy in an adult with plasma exchange- refractory atypical hemolytic uremic syndrome. Am J Hematol. 2010; 85: 976-977. doi:10.1002/ajh.21862 PubMed
41. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007; 25: 1256-1264. doi:10.1038/ nbt1344 PubMed
42. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361: 1676-1687. doi:10.1056/NEJMra0902814 PubMed
43. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H. Alternative pathway of complement in children with diarrhea- associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009; 4: 1920-1924. doi:10.2 215 /CJN.02730409 PubMed
44. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008; 23: 1957-1972. doi:10.1007/s00467-008-0872-4 PubMed
45. Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol. 2004; 41: 81-84. doi:10. 1016/j.molimm.2004.01.003 PubMed
46. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, et al; Dense Deposit Disease Focus Group. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007; 18: 2447-2456. doi:10.1681/ASN.2007030356 PubMed
47. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol. 2007; 20: 605-616. doi:10.1038/modpathol.3800773 PubMed
48. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez- Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20: 1103-1112. doi:10.1681/ASN.2008 10 1028 PubMed
49. Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992; 340: 741-745. doi:10.1016/0140-6736(92)92292-N PubMed
50. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN; Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000; 343: 1156-1162. doi:10.1056/ NEJM200010193431604 PubMed
51. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353: 2219-2228. doi:10.1056/NEJMoa043731 PubMed
52. Favas C, Isenberg DA. B-cell-depletion therapy in SLE-what are the current prospects for its acceptance? Nat Rev Rheumatol. 2009; 5: 711-716. doi:10.1038/nrrheum.2009.218 PubMed
53. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004; 50: 3934-3940. PubMed doi:10.1002/ art.20666
54. Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL, Holers VM, Thurman JM. Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology. 2010; 255: 517-526. doi:10.1148/radiol.09091134 PubMed
55. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007; 25: 1265-1275. doi:10.1038/nbt1342 PubMed
56. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009; 15: 69-78. doi:10.1016/j.molmed. 2008.12.001 PubMed
57. Thielmann M, Marggraf G, Neuhäuser M, Forkel J, Herold U, Kamler M, Massoudy P, Jakob H. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg. 2006; 30: 285-293. doi:1 0. 1016/j.ejcts.2006.04.022 PubMed
58. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F, Dioguardi P, Ruvolo G. Beneficial effects of C1 esterase inhibitor in STelevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg. 2007; 32: 326-332. doi:10.1016/j.ejcts.2007. 04. 038 PubMed
59. Baig K, Nassar R, Craig DM, Quick G Jr, Jiang HX, Frank MM, Lodge AJ, Anderson PA, Jaggers J. Complement factor 1 inhibitor improves cardiopulmonary function in neonatal cardiopulmonary bypass. Ann Thorac Surg. 2007; 83: 1477-1482, discussion 1483. doi:10.1016/j. athoracsur.2006.10.049 PubMed
60. Frank MM, Miletic VD, Jiang H. Immunoglobulin in the control of complement action. Immunol Res. 2000; 22: 137-146. doi:10.1385/IR:22:2-3:137 PubMed
61. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10: 1222-1226. doi:10.1038/nm1121 PubMed
62. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010; 11: 785-797. doi:10.1038/ni.1923 PubMed
63. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov. 2010; 9: 43-56. doi:10.1038/nrlD3011 PubMed
64. Emlen W, Li W, Kirschfink M. Therapeutic complement inhibition: new developments. Semin Thromb Hemost. 2010; 36: 660-668. doi:10.1055/s-0030-1262888 PubMed
65. Hollmer M. Genentech makes its first-ever acquisition. Nat Biotechnol. 2007; 25: 4-5. doi:10.1038/ nbt0107-4 PubMed
66. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990; 249: 146-151. doi:10.1126/science.2371562 PubMed
67. Patel H, Smith RA, Sacks SH, Zhou W. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol. 2006; 17: 1102-1111. doi:10.1681/ ASN.2005101116 PubMed
68. Pratt JR, Jones ME, Dong J, Zhou W, Chowdhury P, Smith RA, Sacks SH. Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol. 2003; 163: 1457-1465. doi:10.1 016/S0002-9440(10)63503-1 PubMed
69. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008; 181: 8068-8076. PubMed
70. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003; 111: 1875-1885. PubMed
71. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005; 115: 2444-2453. doi:10.1172/JCI25208 PubMed
72. He C, Imai M, Song H, Quigg RJ, Tomlinson S. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol. 2005; 174: 5750-5757. PubMed
73. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006; 20: 217-226. doi:10.1096/fj.05-4747com PubMed
74. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002; 8: 582-587. doi:10.1038/nm0602-582 PubMed
75. Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH. Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol. 1999; 162: 4336-4341. PubMed
76. S Reis E, Falcão DA, Isaac L; E SR. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol. 2006; 63: 155-168. PubMed doi:10.1111/j.1365-3083.2006.01729.x
77. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore). 1984; 63: 243-273. PubMed
78. Densen P. Complement Deficiencies and Infection. In: Volanakis JE, Frank MM (eds). The Human Complement System in Health and Disease. New York: Marcel Dekker, Inc.; 1998. p. 409-421.
79. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009; 373: 759-767. doi:10.1016/S0140-6736(09)60001-5 PubMed
80. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007; 40: 560-566. doi:10. 1080/08916930701510673 PubMed
81. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004; 15: 787-795. doi:10.1097/01.ASN.0000115702.2 885 9.A7 PubMed
82. de Córdoba SR, de Jorge EG. Translational minireview series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol. 2008; 151: 1-13. doi:10.1111/j.1365-2249.2007.03552.x PubMed
83. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is protective for lupus disease independent of C3. J Immunol. 2002; 168: 1036-1041. PubMed
84. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002; 31: 424-428. PubMed
85. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000; 105: 1363-1371. doi:10.1172/JC I8621 PubMed
86. Pratt JR, Abe K, Miyazaki M, Zhou W, Sacks SH. In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol. 2000; 157: 825-831. doi:10.1016/S0002-9440(10 )6 4596-8 PubMed
87. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005; 16: 1177-1183. doi:10.1681/ASN.2005 010086 PubMed
88. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx- HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2008; 111: 624-632. doi:10.1182/blood-2007-04-084533 PubMed
89. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007; 204: 1249-1256. doi:10.1084/jem.20070301 PubMed